Asterias Biotherapeutics, Inc.
USPTO PatentsView assignee record - 21 granted patents across 8 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).
The verdict
According to USPTO PatentsView, Asterias ranks #13,872 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 8 technology areas.
- #13,872
- of 49,997 US assignees by volume
- 32nd percentile
- by Innovation Score (29.8/100)
- 11.6
- avg claims per patent
- -76%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R13872 · US Corporation #13,872 · 21 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 21 grants
- MID-PACK #13,872/49,997
- PHOTO-FINISH Acerta Pharma B V
- CPC-NARROW C12N · 8 areas
- INNOV-THIN 29.8/100
- CLAIMS-PAR 11.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -76% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Acerta Pharma B.V. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Asterias’s 29.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Asterias
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Asterias Biotherapeu… · this assignee 30
Asterias Biotherapeu… · this assignee
30 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Asterias's Innovation Score is 29.8/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Asterias?
Each dot is one of Asterias’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Asterias’s own 11.6 claims/patent is at or below the 15.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Asterias's grants concentrate
Asterias Biotherapeutics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (6 grants) versus a trough of 1 in 2018. By volume, Asterias sits between Aprecia Pharmaceuticals LLC and Active Implants LLC.
Asterias's three-year grant acceleration
Asterias Biotherapeutics, Inc. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Asterias's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Aprecia Pharmaceu…
Aprecia Pharmaceuticals LLC
21 patents
- ARB Labs
ARB Labs Inc.
21 patents
- Artika FOR Living
Artika FOR Living Inc.
21 patents
- Ascentage Pharma…
Ascentage Pharma Group Corp Limited
21 patents
- Atlas Copco Airpo…
Atlas Copco Airpower N.V.
21 patents
- Avantec Vascular
Avantec Vascular Corporation
21 patents
- Acerta Pharma B V
Acerta Pharma B.V.
21 patents
- Active Implants
Active Implants LLC
21 patents
- Asterias Biothera… ◀
Asterias Biotherapeutics, Inc.
21 patents
What this shows Asterias holds 21 patents at rank #13,848, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Asterias
By rank, the assignees closest to #13,848 in granted patent volume.
- Aprecia Pharmaceuticals LLC #13,844 · 21 patents
- ARB Labs Inc. #13,845 · 21 patents
- Artika FOR Living Inc. #13,846 · 21 patents
- Ascentage Pharma Group Corp Limited #13,847 · 21 patents
- Atlas Copco Airpower N.V. #13,849 · 21 patents
- Avantec Vascular Corporation #13,850 · 21 patents
- Acerta Pharma B.V. #13,851 · 21 patents
- Active Implants LLC #13,852 · 21 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Asterias's primary technology class.
- Monsanto Technology LLC 1,335 in class
- The Regents of the University of California 1,161 in class
- Novozymes A/S 656 in class
- Immatics Biotechnologies GmbH 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President and Fellows of Harvard College 594 in class
- Massachusetts Institute of Technology 541 in class
- The Trustees of the University of Pennsylvania 537 in class
Asterias's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
30 32nd percentile higher than 32% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 6 | 28.6% |
| 2016 | 2 | 9.5% |
| 2017 | 4 | 19.0% |
| 2018 | 1 | 4.8% |
| 2019 | 4 | 19.0% |
| 2020 | 1 | 4.8% |
| 2021 | 1 | 4.8% |
| 2023 | 1 | 4.8% |
| 2024 | 1 | 4.8% |
Which technologies does Asterias Biotherapeutics, Inc. patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Asterias Biotherapeutics, Inc.'s patent record in context - here's where to go next.
- Asterias Biotherapeutics, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
- Ranked #13,872 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Asterias Biotherapeutics, Inc. against Aprecia Pharmaceuticals LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 29.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.